DOCSLIB.ORG

Antibiofilm Activity of Nystatin, Aspirin and EDTA Against Candida Albicans Isolated from Iraqi Women with Vulvovaginitis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antibiofilm Activity of Nystatin, Aspirin and EDTA Against Candida Albicans Isolated from Iraqi Women with Vulvovaginitis Medico-legal Update, January-March 2021, Vol. 21, No. 1 703 Antibiofilm Activity of Nystatin, Aspirin and EDTA Against Candida albicans Isolated from Iraqi Women with Vulvovaginitis Noor Naser Raheem1, Kais Kassim Ghaima2* 1Research Scholar, M Sc Student, Kamal Al-Samarrai Hospital, Ministry of Health, Baghdad, Iraq, 2Assistant Professor, Institute of Genetic Engineering and Biotechnology for Postgraduate Studies, University of Baghdad, Baghdad, Iraq Abstract The vulvovaginitis candidiasis is often associated with biofilm formation byCandida albicans and using of antifungal agents against C. albicans biofilms is urgently needed. Microtiter plate assay using crystal violet was used for detection the ability of Candida albicans to form biofilm and the microtiter broth dilution method was used for determination the minimum inhibitory concentrations (MICs). Out of 42 Candida albicans isolated from vulvovaginitis, 37 (88%) can produce biofilm at the varying degrees. Twenty-eight (75.7%) isolates could form a strong biofilm. The results of minimum inhibitory concentrations (MICs) of Nystatin, Aspirin and EDTA (Ethylenediaminetetraacetic acid) against 28 C. albicans isolates which formed the strong biofilm, revealed that range of concentrations of Nystatin were (6.25-100 µg/ml), while the MICs of aspirin and EDTA were more than 1000 µg/ml. It was obvious that the Nystatin had the inhibitory activity at the concentrations 6.25 and 12.5 µg/ml. The highest antibiofilm activity by Nystatin were demonstrated at the subinhibitory concentration 50 μg/ml with biofilm eradication percent (75.80%), while the lowest antifungal effect (2.86-10.70%) was at very low concentrations (3.125-6.25 μg/ml). Also, there was an obvious biofilm eradication of Aspirin and EDTA at the concentrations 500 and 1000 μg/ml but the effect of aspirin at the concentration 1000 μg/ml (70.51%) is more than EDTA (60.12%) in contrast with the concentration 500 μg/ml, it was found that the effect of EDTA (51.29%) is more than aspirin (34.25%). In conclusion, the present study highlights the role of Aspirin and EDTA as antibiofilm agents when used with Nystatin which have the ability to inhibit the growth of C. albicans in patients with vulvovaginitis. Keywords: Nystatin, Aspirin, EDTA, C. albicans, Biofilm, Vulvovaginitis. Introduction dimorphism and the ability to adhere and form biofilm on medical device and/or the host mucosal epithelium, Vulvovaginal candidiasis (VVC) is considered enhance the pathogenicity of C. albicans(2). Vulvovaginal as the main infection caused by Candida albicans. candidiasis defined as a disorder characterized by Numerous virulence determinants and escalating signs and symptoms of vaginal inflammation when the resistance to antifungal therapy have contributed to Candida species are found and is an ever living problem its pathogenicity(1). Some virulence factors such as affecting 70–75% of women of reproductive age at least once during their life(3). The evolution of drug resistance of Candida species to conventional antifungal agents Corresponding Author: has been a major medical challenge worldwide; attempt Kais Kassim Ghaima to use the potential antifungal agents with appropriate Assistant Professor, Institute of Genetic Engineering therapy efficacy and minimum effects is considerably and Biotechnology for Postgraduate Studies, growing(4). The mechanism underlying development University of Baghdad, Baghdad, Iraq of antifungal resistance of C. albicans are complex e-mail: [email protected] and involve multiple pathways and genes. Further, 704 Medico-legal Update, January-March 2021, Vol. 21, No. 1 these mechanisms continue to change and evolve and μg/ml). Wells without Nystatin, Aspirin and EDTA challenging the medical clinic (5). The widespread use of were used as a positive control while those without antibiotics, frequent use of indwelling medical devices, Candida were considered as negative controls. After and a trend towards increased patient immunosuppression 24 hours incubation at 37°C, the wells were visually has resulted in a creation of opportunity for clinically inspected for the growth. The MIC was considered as important Candida to form biofilms and there is growing the lowest concentration of Nystatin, Aspirin and EDTA evidence of the importance of Candida biofilms in that inhibits the Yeast growth(8). clinical problems (6). Therefore the aim of this study is investigate the biofilm formation of C. albicans isolates Antibiofilm activity of Nystatin, Aspirin and as the causative agent of vulvovaginitis in Iraqi women, EDTA: This test was performed on four strains that also using of some compounds such as Aspirin and showed strong biofilm formation ability in the biofilm EDTA as antifungal agents against the high antifungal production assay. The effect of different concentrations resistant isolates. of Nystatin (3.125-100 μg/ml), while Aspirin and EDTA (31.25-1000 μg/ml) to inhibit the ability of C. albicans Materials and Method cells to form a biofilm was assessed using the TCP method adopted by Khodavandi et al. (2011) (9). Nearly, Candida albicans isolates: In this study, a total 100 μl of 0.5 McFarland yeast cultures was dispensed of 42 C. albicans clinical strains were collected from into each well of 96-well polystyrene microtiter plates in women patients with vulvovaginitis from three hospitals the presence of 100 μl of the antibiofilm agent at different in Baghdad, Iraq, during the period from September to concentrations, and plates were incubated at 37°C for 48 December 2019. All strains were previously identified hours. Antimicrobial agent free wells served as positive by API Candida system (bioMérieux, France) and controls for the biofilm growth. After incubation, the confirmed using VITEK 2 compact system (bioMérieux, medium and non-adherent cells were removed and wells France). were washed three times with sterile PBS. The plates were air dried and then the dye was resolubilized with Quantitative biofilm production assay: The Colonies from all isolates of fresh C. albicans cultures absolute ethanol. The OD of each well was measured (48 hours) were grown at 37°C in Sabouraud dextrose at 570 nm using ELISA reader (BioTek, Korea). Each broth medium for 24 hours. Biofilm formation was tested assay was performed in triplicates. by adding 100 μl of this standardized cell suspension Statistical Analysis: The Statistical Analysis to wells of microtiter plates that contained 100 μl of System- SAS (2012) (10) program was used to detect fresh Sabouraud dextrose broth media and incubating the effect of difference factors in study percentage. Chi- them at 37°C for 48 hours. Thereafter, the medium was square test was used to significant compare between removed and planktonic cells were removed by washing percentage (0.05 and 0.01 probability). Least significant the biofilms in phosphate buffered saline. After staining difference LSD test (Analysis of Variation-ANOVA) plates with 2% crystal violet for 20 m, excess stain was was used to significant compare between means in this removed using water. The plates were air dried and study. then the dye was resolubilized with absolute ethanol. The optical density (OD) of each well was measured at Results and Discussion 570 nm using Enzyme-Linked Immunosorbent Assay (ELISA) reader (BioTek, Korea). Optical density cut-off Biofilm formation: Out of 42 Candida albicans value (ODc) was calculated using the equation: average isolates, 37 (88%) can produce biofilm at the varying OD of negative control + (3*SD of negative control) (7). degrees. Twenty-eight (75.7%) isolates could form a strong biofilm, while 6 isolates were the moderate Minimum inhibitory concentration of Nystatin, producer, and only 3 isolates were weak biofilm formers. Aspirin and EDTA: Nearly, 100 μl (0.5 McFarland) of Also it was found that five isolates don’t have the ability the C. albicans culture was inoculated into each well of to formation the biofilm (table 1). Microtiter plate assay a 96-well microtiter plate containing 100 μl Nystatin, using crystal violet was used for detection the ability of Aspirin and EDTA at different concentrations (0.39–200 Candida albicans to form biofilm (figure 1). Medico-legal Update, January-March 2021, Vol. 21, No. 1 705 Table 1. Distribution of biofilm formation ability among Candida albicans isolates. Biofilm formation Candida albicans Weak Moderate Strong Negative Total no of Isolate = 42 3 6 28 5 % 7.14% 14.29% 66.67% 11.90% 2 Chi-Square (χ ­­­­­) 12.073 ** ** (P≤0.01). Figure 1. Biofilm formation detection ofCandida albicans isolates by microtiter plate assay. This study revealed that the most of Candida biofilm formers were 12/22 (54.5%). In a previous albicans isolated from Iraqi women patients with study, it was found the Candida biofilms have important vulvovaginitis formed a strong biofilm. Many studies clinical implications since the biofilm associated with demonstrated the ability of Candida albicans clinical Candida or Gardnerella genital infections may act as a isolates to form heterogeneous biofilms. The presence of chlamydial reservoir contributing to the transmission of these communities in vulvovaginitis may explain why C. Chlamydia trachomatis in the population, alongside its albicans infections remain unresponsive to therapy, and dissemination in the female upper genital tract (15). The there was a relationship between biofilm formation and biofilm formation is very important virulence factor in antifungal resistance among Candida isolates (11, 12). The C. albicans, where this species expresses hyphal-specific study of Shreif et al. (2019) (13) in Egypt which included adhesins and regulators required for adhesion. Also, one hundred Candida albicans isolates from patients the morphological dimorphism in Candida albicans with nosocomial infections revealed that the biofilm supports noticeable phagocyte escape mechanism (16). capacity was identified by the microplate method in 58% of C. albicans and the optical density was intense The present study investigated the role of some in 20 isolates, moderate in 21 isolates and mild in 17 compounds as antibiofilm agents against the biofilm isolates. The local study of Mohammed et al. (2017) (14) formation in C.
Load more

Recommended publications
  • Original Article Interaction of Candida Albicans with Fluconazole
    International Journal of Medical Laboratory 2020;7(2):110-120. Original Article Interaction of Candida albicans with Fluconazole/ Clotrimazole: Effect on Hyphae Formation and Expression of Hyphal Wall Protein 1 Sakineh Jam Shahriari1 M.Sc., Fahimeh Alizadeh1* Ph.D. Alireza Khodavandi2 Ph.D. 1Department of Microbiology, Yasooj Branch, Islamic Azad University, Yasooj, Iran. 2Department of Biology, Gachsaran Branch, Islamic Azad University, Gachsaran, Iran. A B S T R A C T Article history Background and Aims: Candida albicans (C. albicans) is the most common Received 20 May 2019 opportunistic human pathogen. Therapeutic options for Candida infections are Accepted 22 Jul 2019 limited to available antifungal drugs. The aim of this study was to investigate Available online 30 May 2020 the effects of fluconazole/clotrimazole (FLU/CLT) on C. albicans hyphae Key words formation. Candida albicans Materials and Methods: We have established the effectiveness of the Clotrimazole combination of FLU/CLT on C. albicans hyphae formation. Interaction of C. Fluconazole Hyphae albicans with combination of FLU/CLT was performed using the CLSI guidelines and time-killing curves. We investigated the anti-hyphal activities of combination of FLU/CLT against C. albicans using XTT and crystal violet assays as well as scanning electron microscopy and expression of HWP1 gene. Results: The interaction of C. albicans with FLU/CLT resulted in synergistic, partial synergistic and indifferent effects. The interaction of FLU/CLT were confirmed by time-killing curves. FLU/CLT combined resulted in the reduction of metabolic activity and hyphae formation in C. albicans. Images taken by scanning electron microscopy indicated the effectiveness on hyphae disruption.
    [Show full text]
  • Antibiofilm Efficacy of Tea Tree Oil and of Its Main Component Terpinen-4-Ol Against Candida Albicans
    ORIGINAL RESEARCH Periodontics Antibiofilm efficacy of tea tree oil and of its main component terpinen-4-ol against Candida albicans Renata Serignoli Abstract: Candida infection is an important cause of morbidity FRANCISCONI(a) and mortality in immunocompromised patients. The increase in its Patricia Milagros Maquera incidence has been associated with resistance to antimicrobial therapy HUACHO(a) and biofilm formation. The aim of this study was to evaluate the Caroline Coradi TONON(a) efficacy of tea tree oil (TTO) and its main component – terpinen-4-ol – Ester Alves Ferreira BORDINI(a) against resistant Candida albicans strains (genotypes A and B) identified by molecular typing and against C. albicans ATCC 90028 and SC 5314 Marília Ferreira CORREIA(a) reference strains in planktonic and biofilm cultures. The minimum Janaína de Cássia Orlandi inhibitory concentration, minimum fungicidal concentration, and SARDI(b) rate of biofilm development were used to evaluate antifungal activity. Denise Madalena Palomari Results were obtained from analysis of the biofilm using the cell (a) SPOLIDORIO proliferation assay 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H- tetrazolium-5-carboxanilide (XTT) and confocal laser scanning (a) Universidade Estadual Paulista – Unesp, microscopy (CLSM). Terpinen-4-ol and TTO inhibited C. albicans School of Dentistry of Araraquara, Department of Physiology and Pathology, growth. CLSM confirmed that 17.92 mg/mL of TTO and 8.86 mg/mL Araraquara, SP, Brazil of terpinen-4-ol applied for 60 s (rinse simulation) interfered with (b) Universidade Estadual de Campinas – biofilm formation. Hence, this in vitro study revealed that natural Unicamp, School of Dentistry of Piracicaba, substances such as TTO and terpinen-4-ol present promising results Department of Physiological Sciences, for the treatment of oral candidiasis.
    [Show full text]
  • Eczema Low Cost (TALC) David Chandler 13 in the Community Najeeb Ahmad Safdar & Jane Sterling 6 ABSTRACTS ESSENTIAL DRUGS in DERMATOLOGY Journal Extracts and 1
    An International Journal for Community Skin Health EDITORIAL: PUBLIC HEALTH AND SKIN DISEASE R J Hay DM FRCP record which is often unrecognised. For International Foundation of instance, in the early part of the twenti- Dermatology eth century many countries had policies Professor of Dermatology for the control of scalp ringworm which Faculty of Medicine and Health Sciences ranged from school exclusion orders to special treatment facilities. It resulted in Queen’s University, Belfast, UK partial control but, in the absence of an effective remedy, elimination remained ost of the work of dermato- a distant goal. With the discovery of logists is concerned with the drug, griseofulvin, the potential to the treatment of individ- provide a wider programme based on Mual patients to the highest standards the treatment of communities became achievable with the facilities and skills possible and, in some areas, there was a available. However, it is seldom possible concerted effort to eliminate tinea capi- to apply this to large populations in tis using control teams. Afghan refugee child most parts of the developing world, par- Yaws and leprosy are further exam- ticularly where the lack of resources and ples of diseases where control measures, sparse populations make the adoption of backed by international collaboration, this model of health care unattainable. have focused on elimination of infection In assessing the needs for these groups a by early identification of cases and con- different approach is necessary. tacts and mass drug treatment. Public Health and Skin Skin Disease and the Western Disease World Dermatological public health has sel- In recent years, the focus of public dom been prioritised as a key objec- health in 'western world' dermatology tive in the overall management of has concentrated on the control of the At a Health Centre, Afgooye, Somalia skin diseases, although it has a strong modern epidemic of a non-infectious Photos: Murray McGavin CONTENTS J Comm Dermatol 2005; 2: 1–16 Issue No.
    [Show full text]
  • Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Therapeutic Class Overview Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Therapeutic Drug Class
    BUREAU FOR MEDICAL SERVICES WEST VIRGINIA MEDICAID EFFECTIVE PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA 07/01/13 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL. Version 2013.3c Prior authorization for a non-preferred agent in any category will be given only if there has been a trial of the preferred brand/generic equivalent or preferred formulation of the active ingredient, at a therapeutic dose, that resulted in a partial response with a documented intolerance. Prior authorization of a non-preferred isomer, pro-drug, or metabolite will be considered with a trial of a preferred parent drug of the same chemical entity, at a therapeutic dose, that resulted in a partial response with documented intolerance or a previous trial and therapy failure, at a therapeutic dose, with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. (The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.) Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC drugs are not covered unless specified. PA criteria for non-preferred agents apply in addition to general Drug Utilization Review policy that is in effect for the entire pharmacy program, including, but not limited to, appropriate dosing, duplication of therapy, etc. The use of pharmaceutical samples will not be considered when evaluating the members’ medical condition or prior prescription history for drugs that require prior authorization.
    [Show full text]
  • A Ketoconazole Susceptibility Test for Malassezia Pachydermatis Using Modified Leeming–Notman Agar
    Journal of Fungi Article A Ketoconazole Susceptibility Test for Malassezia pachydermatis Using Modified Leeming–Notman Agar Bo-Young Hsieh 1,2, Wei-Hsun Chao 3, Yi-Jing Xue 2 and Jyh-Mirn Lai 2,* 1 Lugu Township Administration, Nanto County 55844, Taiwan; [email protected] 2 College of Veterinary Medicine, National Chiayi University, No. 580, XinMin Rd., Chiayi City 60054, Taiwan; [email protected] 3 Department of Hospitality Management, WuFung University, Chiayi City 60054, Taiwan; [email protected] * Correspondence: [email protected]; Tel.: +886-5-2732920; Fax: +886-5-2732917 Received: 18 September 2018; Accepted: 14 November 2018; Published: 16 November 2018 Abstract: The aim of this study was to establish a ketoconazole susceptibility test for Malassezia pachydermatis using modified Leeming–Notman agar (mLNA). The susceptibilities of 33 M. pachydermatis isolates obtained by modified CLSI M27-A3 method were compared with the results by disk diffusion method, which used different concentrations of ketoconazole on 6 mm diameter paper disks. Results showed that 93.9% (31/33) of the minimum inhibitory concentration (MIC) values obtained from both methods were similar (consistent with two methods within 2 dilutions). M. pachydermatis BCRC 21676 and Candida parapsilosis ATCC 22019 were used to verify the results obtained from the disk diffusion and modified CLSI M27-A3 tests, and they were found to be consistent. Therefore, the current study concludes that this new novel test—using different concentrations of reagents on cartridge disks to detect MIC values against ketoconazole—can be a cost-effective, time-efficient, and less technically demanding alternative to existing methods.
    [Show full text]
  • First-Line Treatment of Oral Candidiasis in Adults
    No. 628017 First-line Treatment of Oral Candidiasis in Adults Developed in collaboration with an advisory committee consisting of Québec clinicians and experts. Validated by the Comité d’excellence clinique en usage optimal du médicament, des protocoles médicaux nationaux et ordonnances of the Institut national d’excellence en santé et en services sociaux (INESSS). CLINICAL SITUATION OR TARGET POPULATION Person aged 18 years and older with one or several of the following clinical signs and symptoms: ► Sensation of burning, discomfort or general pain in the mouth or at the corners of the mouth, which worsens when eating food1 ► White patches that can be scraped away more or less easily; redness on the mucous membranes of the mouth. ► Cracked skin or slight bleeding at the corners of the mouth, which may extend to marionette lines. ► Total or partial loss of papillae on the surface of the tongue. CONTRAINDICATIONS TO THE APPLICATION OF THIS PROTOCOL ► Contraindication or history of allergic reaction to the recommended medication. ► Known case of refractory oral candidiasis. ► Oral candidiasis recurrence within one month of initial treatment. ► White patches that appear unilaterally on the tongue or cannot be scraped away. ► Bite or sore marks on the inside of the cheeks or on the tongue. ► Gum or submaxillary swelling. ► Surgery, injury, trauma, cut, burns in the mouth, or oral health problems (e.g. viral, bacterial or fungal infections) within the past two (2) weeks. ► Oral pain, localized or unilateral. ► Difficulty in swallowing, pain or burning sensation in the sternum or chest (suggesting esophageal candidiasis). ► Constant burning sensation that lessens when eating food (suggesting stomatopyrosis).
    [Show full text]
  • Abnormal Vaginal Discharge: What Does and Does Not Work in Treating Underlying Causes
    AE_French.1104.final 10/18/04 11:03 AM Page 890 Applied Evidence N EW R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE Abnormal vaginal discharge: What does and does not work in treating underlying causes Linda French, MD Michigan State University, East Lansing, Mich Jennifer Horton, DO Genesys Regional Medical Center Family Practice Residency, Grand Blanc, Mich Michelle Matousek, DO Henry Ford Health System, Detroit, Mich Practice recommendations part of this article, “Abnormal vaginal discharge: Using office diagnostic testing more effectively” ■ Treat bacterial vaginosis with oral or intravagi- (JFP 2004; 53[10]:805–814), abnormal discharge nal metronidazole or with clindamycin (SOR: is more likely to be bacterial vaginosis or no A); recurrences are common (SOR: C). pathogen at all. Potential delay in diagnosis and treatment of a sexually transmitted disease is ■ Oral and intravaginal imidazoles are also a concern. Increasing resistance of Candida equally effective in the treatment of sp. to imidazoles is associated with indiscriminate candidiasis (SOR: A); alternate therapies use of over-the-counter products. for resistant cases have been little studied. ■ Oral metronidazole is the standard ■ BACTERIAL VAGINOSIS therapy for trichomoniasis (SOR: A). The standard treatment for bacterial vaginosis Oral tinidazole, newly available in the (BV) has been oral metronidazole (Flagyl) 500 mg US in 2004, should be used in resistant twice daily for 5 to 7 days. Intravaginal 0.75% cases (SOR: B). metronidazole gel (MetroGel) has been shown to be as effective as oral metronidazole (SOR: A).1,2 Oral metronidazole can cause nausea and ntifungal medications for intravaginal use abdominal pain in some patients; vaginal treat- have been available in the United States ment may be preferable for them.
    [Show full text]
  • Antifungal Drugs
    Antifungal Drugs Antifungal or antimycotic drugs are those agents used to treat diseases caused by fungus. Fungicides are drugs which destroy fungus and fungistatic drugs are those which prevent growth and multiplication of fungi. Collectively these drugs are often referred to as antimycotic or antifungal drugs. General characteristics of fungus: Fungi of medical significance are of two groups: Yeast Unicellular (Candida, Crytococcus) Molds Multicellular; filamentous consist of hyphae (Aspergillus, Microsporum, Trichophyton) They are eukaryotic i.e. they have well defined nucleus and other nuclear materials. They are made of thin threads called hyphae. The hyphae have a cell wall (like plant cells) made of a material called chitin. The hyphae are often multinucleate. They do not have chlorophyll, can’t make own food by photosynthesis, therefore derive nutrients by means of saprophytic or parasitic existence. Cell membrane is made up of ergosterol. Types of fungal infections: Fungal infections are termed as mycoses and in general can be divided into: Superficial infections: Affecting skin, nails, scalp or mucous membranes; e.g. Tinea versicolor Dermatophytosis: Fungi that affect keratin layer of skin, hair and nail; e.g. Tinea pedis, rign worm infection. Candidiasis: Yeast infections caused by (Malassezia pachydermatis), oral thrush (oral candidiasis), vulvo-vaginitis, nail infection. Systemic/Deep infections: Affecting deeper tissues and organ they usually affect lungs, heart and brain leading to pneumonia, endocarditis and meningitis. Systemic infections are associated with immunocompromised patients, these diseases are serious and often life threatening due to the organ involved. Some of the serious systemic fungal infections in man are candidiasis, cryptococcal meningitis, pulmonary aspergillosis.
    [Show full text]
  • Antifungal and Antibiotic Powders
    ANTIFUNGAL AND ANTIBIOTIC POWDERS Antifungals: Econazole Powder, Ketoconazole Powder, Nyamyc (nystatin) Powder, Nystop (nystatin) Powder Antibiotics: Mupirocin Powder, Tobramycin Powder, Vancomycin Powder RATIONALE FOR INCLUSION IN PA PROGRAM Background Pharmacy compounding is an ancient practice in which pharmacists combine, mix or alter ingredients to create unique medications that meet specific needs of individual patients. Some examples of the need for compounding products would be: the dosage formulation must be changed to allow a person with dysphagia (trouble swallowing) to have a liquid formulation of a commercially available tablet only product, or to obtain the exact strength needed of the active ingredient, to avoid ingredients that a particular patient has an allergy to, or simply to add flavoring to medication to make it more palatable. The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Pharmacy powder products have the potential for misuse. Misuse of these powder products is quite common and it is important to inform patients about the possible complications due to overuse of these drugs. Regulatory Status FDA approved indication: Antifungal agents kill fungi or inhibit their growth. Antifungals that kill fungi are called fungicidal while those that inhibit their growth are called fungistatic. Antibiotics, or antimicrobials, are medications that destroy or slow down the growth of bacteria.
    [Show full text]
  • Sodium Salicylate Influences the Pseudomonas Aeruginosa Biofilm
    International Journal of Molecular Sciences Article Sodium Salicylate Influences the Pseudomonas aeruginosa Biofilm Structure and Susceptibility Towards Silver Erik Gerner 1,2,3,* , Sofia Almqvist 2 , Peter Thomsen 1 , Maria Werthén 1,3 and Margarita Trobos 1,3,* 1 Department of Biomaterials, The Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden; [email protected] (P.T.); [email protected] (M.W.) 2 Mölnlycke Health Care AB, 415 02 Gothenburg, Sweden; sofi[email protected] 3 Center for Antibiotic Resistance Research (CARe), University of Gothenburg, 405 30 Gothenburg, Sweden * Correspondence: [email protected] (E.G.); [email protected] (M.T.) Abstract: Hard-to-heal wounds are typically infected with biofilm-producing microorganisms, such as Pseudomonas aeruginosa, which strongly contribute to delayed healing. Due to the global challenge of antimicrobial resistance, alternative treatment strategies are needed. Here, we investigated whether inhibition of quorum sensing (QS) by sodium salicylate in different P. aeruginosa strains (QS-competent, QS-mutant, and chronic wound strains) influences biofilm formation and tolerance to silver. Biofilm formation was evaluated in simulated serum-containing wound fluid in the presence or absence of sodium salicylate (NaSa). Biofilms were established using a 3D collagen-based biofilm model, collagen coated glass, and the Calgary biofilm device. Furthermore, the susceptibility of 48-h-old biofilms formed by laboratory and clinical strains in the presence or absence of NaSa towards silver was evaluated by assessing cell viability. Biofilms formed in the presence of NaSa were more susceptible to silver and contained reduced levels of virulence factors associated with biofilm development than those formed in the absence of NaSa.
    [Show full text]